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Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths. The average
survival and 5-year survival rates of HCC patients still remains poor. Thus, there is an urgent need to better
understand the mechanisms of cancer progression in HCC and to identify useful biomarkers to predict prognosis.
Methods: Public data portals including Oncomine, The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus
(GEO) profiles were used to retrieve the HCC-related microarrays and to identify potential genes contributed to cancer
progression. Bioinformatics analyses including pathway enrichment, protein/gene interaction and text mining were
used to explain the potential roles of the identified genes in HCC. Quantitative real-time polymerase chain reaction
analysis and Western blotting were used to measure the expression of the targets. The data were analysed by SPSS 20.
0 software.
Results: We identified 80 genes that were significantly dysregulated in HCC according to four independent
microarrays covering 386 cases of HCC and 327 normal liver tissues. Twenty genes were consistently and stably
dysregulated in the four microarrays by at least 2-fold and detection of gene expression by RT-qPCR and western
blotting showed consistent expression profiles in 11 HCC tissues compared with corresponding paracancerous
tissues. Eleven of these 20 genes were associated with disease-free survival (DFS) or overall survival (OS) in a
cohort of 157 HCC patients, and eight genes were associated with tumour pathologic PT, tumour stage or vital
status. Potential roles of those 20 genes in regulation of HCC progression were predicted, primarily in association
with metastasis. INTS8 was specifically correlated with most clinical characteristics including DFS, OS, stage,
metastasis, invasiveness, diagnosis, and age.
Conclusion: The significantly dysregulated genes identified in this study were associated with cancer progression
and prognosis in HCC, and might be potential therapeutic targets for HCC treatment or potential biomarkers for
diagnosis and prognosis.
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Hepatocellular carcinoma (HCC) is the third leading
cause of cancer-related deaths [1]. There are 750,000
new cases of HCC and nearly 700,000 deaths each year,
making this a particularly lethal form of cancer [2]. Over
the past decade major progress has been made in our
understanding of the risk factors and molecular path-
ways driving liver carcinogenesis, and these advances
have led to substantial opportunities for HCC preven-
tion, surveillance, early diagnosis, prediction of progno-
sis, and therapy [1]. However, the average survival of
HCC patients is normally between 6 and 20 months [3],
and long-term prognosis is poor with reported 5-year
survival rates ranging from 17 to 53 % [4]. Thus, there is
an urgent need to better understand the mechanism of
cancer progression and development in HCC and to
identify useful biomarkers for diagnosis and prognosis.
High-throughput profiling technologies such as micro-
arrays and, more recently, next-generation sequencing
have become invaluable tools for biomedical research,
and large amounts of data generated by those tools,
including mRNA expression, DNA methylation, and
microRNA expression, are collected in public archives
such as the major public projects The Cancer Genome
Atlas (TCGA) [5] and the International Cancer Genome
Consortium [6], and the most prominent primary data
archives, ArrayExpress [7], Gene Expression Omnibus
(GEO) [8], Oncomine [9] and the databases of the Inter-
national Nucleotide Sequence Database Collaboration
[10]. The wide range of those databases, the various
ways in which publicly archived gene expression data are
being used in support of new studies, and reuse of these
public data can be very powerful [11]. In particular,
reusing of the data has the potential to predict treatment
response and disease progression and was advantageous
to develop precision therapies [12]. For example, based
on data retrieved from Oncomine, TCGA, and GEO, Liu
et al. identified several genes associated with ovarian
cancer progression [13] and drug resistance [14]. In a
similar manner, we identified that upregulation of E2F
transcription factor 3 is associated with poor prognosis
in HCC [15]. In the present study, using data of mRNA
expression, DNA methylation, and clinical data retrieved
from Oncomine, GEO, and the TCGA cohort, we identi-
fied a group of genes associated with cancer progression
and prognosis in HCC.Methods
Samples
All patients who underwent curative hepatectomy for
primary HCC at the First Affiliated Hospital of Guangxi
Medical University between March 2015 and September
2015 were eligible for inclusion in this study. Total of11 HCCs and the matched paracancerous tissues were
collected during surgery and stored in a liquid nitrogen
tank until use for mRNA isolation and protein extraction.
The study was endorsed by the Ethics Committee of
Guangxi Medical University and was performed according
to the Declaration of Helsinki, 2013 edition. All patients
received an explanation of the aims of the study and
signed informed consent.
mRNA isolation and quantitative real-time polymerase
chain reaction (RT-qPCR) analysis
Total RNA from 11 HCC and their matched paracan-
cerous tissues was isolated using a miRNeasy Mini Kit
(Qiagen, Hilden, Germany). RNA was quantified by spec-
trophotometry on a NanoDrop 2000 (Thermo Scientific,
DE, USA). A total of 2 μg RNA was subjected to cDNA
synthesis using the miScript II RT Kit (Qiagen, Hilden,
Germany). RT-qPCR was performed with the QuantiFast
SYBR Green PCR Kit (Qiagen, Hilden, Germany). Data
were collected with the StepOnePlus Real-Time PCR
System (ABI, CA, USA) according to the manufacturer’s
instructions. The gene expression was compared in each
HCC sample and the matched paracancerous tissue, and
then the homogeneity of variance in all samples was ana-
lysed using the t-test. The RT-qPCR gene-specific primers
were as follows: TBCE: forward primer, 5′-AGGCCAACA
GATGTTCTCCAG-3′, reverse primer, 5′-CAGGGGGTT
TCTTAGGCAGG-3′; INTS8: forward primer, 5′-AACT
GAGAGTTCTACTGCTGGA-3′, reverse primer, 5′-GC





3′; MARCO: forward primer, 5′-GGGGACACAGGACT
TCAAGG-3′, reverse primer, 5′-CCCTGTTCTCCCTT
CACACC-3′; DNASE1L3: forward primer, 5′-AGCCCT
TTGTGGTCTGGTTC-3′, reverse primer, 5′-CGTCCG





(used as the control): forward primer, 5′-GAAGGTGAA
GGTCGGAGT-3′, reverse primer, 5′-GAAGATGGTGA
TGGGATTT-3′.
Protein extraction and western blotting
Total protein was extracted from HCC and paracancer-
ous tissues with RIPA lysis buffer (Solarbio, Beijing,
China) and proteinconcentration was determined using
an Enhanced BCA Protein Quantification Kit (KeyGEN
BioTECH, Jiangsu, China). Then the samples were sepa-
rated by Novex NuPAGE SDS-PAGE Gel System (Thermo
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PVDF membrane using the Bio-Rad Criterion System
(Bio-Rad, CA, USA). Membranes were blocked with 8 %
non-fat dry milk in PBS containing 0.1 % Tween-20
(0.1 % TBST, pH7.4) for 1 h. Membranes were incu-
bated with antibodies specific for human INTS8 (rabbit
polyclonal antibody, 1:750 dilutions; Proteintech, Hubei,
China) and GAPDH (rabbit polyclonal antibody, 1:1,000
dilution; Boster, Hubei, China) overnight at 4 °C. After
3 washings with 0.1 % TBST for 5 min, horseradish
peroxidase-conjugated goat anti-rabbit secondary anti-
bodies (1:5,000 dilution; Bioss, Beijing, China) were
applied, followed by washings with 0.1 % TBST for 5
min each at room temperature (RT). The bound immuno-
complexes were detected using ECL+ reagent (GE
Healthcare Bio-Sciences, NJ, USA) with a FluorChem
M system (Proteinsimple, CA, USA).Gene expression profiles
The genes significantly dysregulated in HCC were identi-
fied based on the 4 microarrays, Chen Liver microarray
(104 HCCs vs. 76 liver tissues), Roessler Liver micro-
array (22 HCCs vs. 21 liver tissues), Roessler Liver 2
microarray (225 HCCs vs. 220 liver tissues) and Wurm-
bach Liver microarray (35 HCCs vs. 10 liver tissues),
which are all deposited in Oncomine database (https://
www.oncomine.org/resource/login.html) [9]. The 4 mi-
croarrays together covering total of 386 cases of HCCs
and 327 cases of normal liver tissues. The rank for a
gene is the median rank for that gene across each of the
analyses. DNA methylation, mRNA expression, and
clinical data of 379 HCC patients in a TCGA cohort
were retrieved from cBioPortal for Cancer Genomics
(http://cbioportal.org) [16, 17], but only 157 samples
with matched gene expression data, prognosis data and
most of the other clinical data were used to analyze the
clinical importance of the target genes. mRNA expression
data associated with HCC metastasis were retrieved from
microarray GDS3091 [18] and GDS274 [19], which
were deposited in the GEO profiles databases (http://
www.ncbi.nlm.nih.gov/geoprofiles/) [8].Bioinformatics analyses
Enrichment of the biological process and cellular
component of a group of genes was determined using
the DAVID online tool (http://david.abcc.ncifcrf.gov/)
[20, 21]. Protein/gene-protein/gene interaction analysis
was performed using the GeneMANIA online tool
(http://www.genemania.org/) [22, 23]. Function prediction
based on text mining was performed using the Coremine
Medical online database (http://www.coremine.com/
medical/) [24].Data analysis
The data were analysed by SPSS 20.0 software. The
mRNA expression of a gene is presented as the mean ±
SD. Homogeneity of variance was analysed using the t-
test. Expression values of a gene were dichotomised
into high and low expression using the median as a cutoff
for analysis of clinical importance in a TCGA cohort, as
described in a previous study [25]. The probability of
survival and its significance was calculated using the
Kaplan-Meier method and log-rank test, respectively. A
Cox proportional hazard model was performed for multi-
variate analysis of prognosis. The correlation between
gene expression and clinicopathologic characteristics was
evaluated by Pearson’s χ2 test (two-sided). The correlation
between DNA methylation and gene expression was
analysed using bivariate correlations. P values < 0.05 were
considered to indicate statistically significant differences.Results
Retrieval of significantly dysregulated genes in HCC
Four independent microarrays deposited in the Oncomine
database were selected to identify genes associated with
cancer development and progression in HCC. These
microarrays were Chen Liver Statistics covering 104
cases of HCC and 76 cases of liver tissue, Roessler Liver
Statistics covering 22 cases of HCC and 21 cases of
liver tissue, Roessler Liver 2 Statistics covering 225
cases of HCC and 220 cases of liver tissue, and Wurm-
bach Liver Statistics covering 35 cases of HCC and 10
cases of liver tissues. Based on analysis of these four in-
dependent microarrays, 40 genes that were significantly
upregulated (P < 1.36E-10) and 40 genes that were
significantly downregulated (P < 1.31E-10) in HCC were
retrieved (Fig. 1). Analysis of the 80 genes by the
DAVID online tool indicated that cell cycle was the top
biological process, covering 17 genes, and microtubule
cytoskeleton was the top cellular component, covering
14 genes (Additional file 1: Table S1).
Among the 80 genes that were dysregulated in HCCs
according to four independent microarrays covering a
total of 386 cases of HCC and 327 cases of normal
liver tissues, nine genes (CAP2, PTTG1, TOP2A,
GMNN, GPC3, UBE2C, UBAP2L, TBCE, and INTS8)
were consistently and stably upregulated and 18 genes
(CXCL14, VIPR1, CLEC4M, MARCO, CLEC1B, NAT2,
FCN2, EGR1, DNASE1L3, MT1F, CRHBP, LCAT,
PAMR1, ACSM3, MT1G, MT1X, SRPX, and MT1H)
were consistently and stably downregulated in HCC,
by least 2-fold (Fig. 1; Table 1). Among the above 27
genes, seven genes—CAP2, GMNN, PTTG1, TBCE,
TOP2A, UBE2C, and FCN2—encode proteins associ-
ated with cell cycle and microtubule cytoskeleton
(Additional file 1: Table S1). Protein/gene-protein/gene
Fig. 1 The 80 genes that were significantly dysregulated in hepatocellular carcinomas according to four independent microarrays retrieved from
the Oncomine database. a The top 40 genes that were significantly upregulated in four microarrays. b The top 40 genes that were significantly
downregulated in four microarrays. The four microarrays cover a total of 386 cases of hepatocellular carcinomas and 327 cases of normal liver tissue:
(1) Chen Liver Statistics, 104 cases of hepatocellular carcinoma and 76 cases of liver tissue; (2) Roessler Liver Statistics, 22 cases of hepatocellular
carcinoma and 21 cases of liver tissue; (3) Roessler Liver 2 Statistics, 225 cases of hepatocellular carcinoma and 220 cases of liver tissue; (4) Wurmbach
Liver Statistics, 35 cases of hepatocellular carcinoma and 10 cases of liver tissue. The rank for a gene is the median rank for that gene across each of
the analyses. The P value given for a gene is for the median-ranked analysis. The genes labelled in red and in blue were significantly and consistently
up- and downregulated in the four microarrays, respectively
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interrelationships of these genes in HCC. As shown in
Additional file 2: Figure S2, the 27 proteins/genes directly/
indirectly interacted with each other via co-localisation,
genetic interactions, shared common pathways, and
protein domains, and, in particular, co-expression, and 10of them—VIPR1, DNASE1L3, SRPX, MT1H, CXCL14,
CLEC4M, CRHBP, GPC3, NAT2, andMARCO—interacted
with at least 14 other genes, more than half of all the
genes in the interaction network (Additional file 2: Figure
S2). Moreover, these genes were also those that were
dysregulated at least 4-fold in HCC (Table 1).
Table 1 Genes that were stably and consistently dysregulated in 386 cases of hepatocellular carcinoma compared with 327 cases of
normal liver tissues according to four independent microarrays retrieved from the Oncomine database, and their associations with
hepatocellular carcinoma
Gene Independent microarray data (Fold change) No. of
articlesa











TBCEb Up 2.125 2.403 2.822 2.419 - -
INTS8b Up 2.393 3.102 2.340 2.115 - -
UBAP2Lb Up 2.108 2.959 2.819 2.742 - -
GMNNb Up 3.362 7.340 4.696 3.394 1 Potential oncogene [38]
UBE2C Up 4.733 3.661 3.422 5.113 4 Cancer progression and poor prognosis [39]
PTTG1 Up 4.688 4.741 5.773 10.622 9 Angiogenesis, progression, and poor prognosis
[40, 41], therapeutic target [42]
CAP2 Up 3.526 4.254 5.790 8.569 10 Multistage hepatocarcinogenesis [43], early
detection [44]
TOP2A Up 2.663 11.236 8.292 13.321 11 Early age onset, shorter patient survival and
chemoresistance [45]
GPC3 Up 16.826 26.693 28.236 76.162 199 Diagnosis [29], cell proliferation and invasion [28];
prediction of recurrence [30]
VIPR1b Down 9.979 5.310 7.202 4.855 - -
CLEC4Mb Down 28.107 9.276 4.361 36.431 - -
MARCOb Down 11.333 6.107 3.984 20.154 - -
DNASE1L3b Down 8.386 12.378 7.653 10.303 - -
PAMR1b Down 2.726 2.381 2.473 2.917 - -
ACSM3b Down 2.902 6.135 4.836 11.262 - -
CLEC1Bb Down 6.600 6.605 4.748 36.770 1 Downregulated in a cohort of 65 pairs of human
HCCs [46]
MT1Fb Down 14.107 18.140 15.749 9.680 1 Inhibition of cancer growth [47]
CRHBPb Down 16.565 7.020 4.822 46.837 1 Downregulated in a cohort of 65 pairs of human
HCCs [46]
LCATb Down 4.917 8.507 8.064 7.435 1 LCAT activity correlated with serum albumin and
serum bilirubin level [48]
MT1Xb Down 10.812 11.558 8.227 6.903 1 HCC-related [49]
SRPXb Down 4.929 5.104 5.879 7.202 1 Proliferation, migration and invasiveness [50]
MT1Hb Down 13.846 9.037 8.473 7.723 1 Potential tumour suppressor [51]
FCN2b Down 10.881 9.089 6.299 44.688 2 HBV- and HCV-related HCC [52], FCN2 haplotypes
associate with HCC [53]
CXCL14b Down 12.903 9.667 10.940 13.977 4 Potential diagnostic marker [54]; rs2237062
polymorphism influences HBV-related HCC
progression [52, 55]; potential tumour suppressor [56]
MT1Gb Down 13.065 11.134 11.160 11.187 4 Tumour suppressor gene [51, 57], biomarker [58]
EGR1 Down 3.541 10.547 6.769 9.241 12 Critical for hepatocarcinogenesis [59]
NAT2 Down 8.024 16.088 13.999 36.890 14 NAT2 polymorphism is risk factor for developing HCC
[60], NAT2 activity is critical in smoking-related
hepatocarcinogenesis [61]
aNo. of articles was based on a search in the PubMed database
bpoorly studied genes in HCC
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Among the 27 genes, the associations of seven with HCC
are relatively well studied and described in published pa-
pers. However, the relationship of the remaining 20 geneswith HCC was poorly understood, and these genes were
selected for further analyses (Table 1). The expression of
eight genes that were randomly selected from the 20 genes
was measured by RT-qPCR in 11 tissues of HCC patients
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shown in Fig. 2a, the expression of TBCE and INTS8
was increased, whereas that of VIPR1, CLEC4M,
MARCO, DNASE1L3, CRHBP, and FCN2 was decreased
in HCC tissues, although the changes in TBCE and
VIPR1 expression were not statistically significant.
Compared with the average expression in paracancer-
ous tissues, the expression of INTS8 in HCC was
upregulated with 2.06-fold and the expression of
CLEC4M, MARCO, DNASE1L3, CRHBP, and FCN2 was
downregulated with 3.83-, 5.70-, 5.63-, 3.87-, and 8.94-
fold, respectively. All results of gene expression deter-
mined by RT-qPCR were completely consistent with
their expression identified by the four independent mi-
croarrays (Fig. 1; Table 1). Furthermore, a significant
increase at the protein level of INTS8 was observed in
HCC tissues compared with corresponding paracancer-
ous tissues (Fig. 2b), which was consistent with its
expression at the mRNA level.Analysis of clinical importance
The clinical importance in HCC of the 20 selected genes
(Table 1) was evaluated on the basis of TCGA clinical
data. A total of 379 HCC patient samples with clinical
data in a cohort of TCGA were retrieved. Among these,
157 samples with mRNA expression values were selected
for analysis of the relationship between genes and clin-
ical characteristics. The expression values of a gene were
categorised as high or low according to the median value
in accordance with a previous study [25].Fig. 2 Measurement of gene expression at mRNA and protein level. a mRN
matched paracancerous tissue. * P < 0.05; ** P < 0.01. b Protein expression o
corresponding paracancerous tissues. The intensity of protein bands was mA total of 11 genes were associated with DFS and/or
OS (Table 2); among those, low expression of ACSM3
and CXCL14 was associated with poor DFS, and low
expression of CRHBP, DNASE1L3, FCN2, MT1X, and
VIPR1 was associated with poor OS (Fig. 3, Table 2).
Four genes were associated with both DFS and OS: high
expression of INTS8 in HCC patients, and low expres-
sion of LCAT, MARCO, and PAMR1, was associated with
poor DFS and OS (Fig. 4, Table 2). To elucidate whether
any of the above genes was an independent factor for
predicting patient survival, we performed multivariate
analyses of tumour stage, tumour pathologic PT,
tumour residual, tumour status, vital status, age, gen-
der, and the 11 genes by a Cox proportional hazards
model (Table 3). We found that stage (P = 0.050),
tumour status (P = 0.001), DNASE1L3 expression (P =
0.042), and INTS8 expression (P = 0.023) were inde-
pendent risk prognostic factors for OS in HCC patients,
although no gene was found to be an independent
prognostic factor for DFS (data not shown).
Six genes were associated with tumour pathologic PT
and tumour stage (Table 4); among these, high expres-
sion of INTS8 and UBAP2L, and low expression of
ACSM3, FCN2, LCAT, and MT1G, was significantly asso-
ciated with metastatic tumour and late stage (P ≤ 0.05). In
particular, UBAP2L was markedly and highly expressed in
T2 tumours (72.5 % vs. 27.5 %) and LCAT was lowly
expressed in T2 tumours (30.0 % vs. 70.0 %) and highly
expressed in T1 tumours (72.6 % vs. 27.4 %). In addition,
LCAT was highly expressed in stage I tumours (71.2 % vs.
28.8 %).A expression of genes in 11 tissues of HCC patients compared with
f INTS8 in four tissues of HCC patients compared with expression in
easured by Image J software.. T, HCC tissue; P, paracancerous tissue
Table 2 The associations of 11 genes with disease-free survival (DFS) and/or overall survival (OS) of patients with hepatocellular
carcinoma in a TCGA cohort, analysed using Kaplan-Meier survival plots
DFS (Median) OS (Median)
95 % Confidence Interval 95 % Confidence Interval
Estimate Std. Error Lower Boundary Upper Boundary Estimate Std. Error Lower Boundary Upper Boundary
ACSM3 H 24.800 7.587 9.930 39.670
L 14.400 2.391 9.714 19.086
Overall 19.300 3.428 12.581 26.019
CXCL14 H 29.300 10.355 9.004 49.596
L 16.400 2.222 12.045 20.755
Overall 19.300 3.428 12.581 26.019
INTS8 H 14.400 2.408 9.681 19.119 21.700 5.048 11.805 31.595
L 27.200 4.266 18.839 35.561 53.300 10.531 32.659 73.941
Overall 19.300 3.428 12.581 26.019 37.800 8.792 20.568 55.032
LCAT H 29.300 5.287 18.937 39.663 55.600 13.029 30.063 81.137
L 14.800 2.129 10.628 18.972 21.700 5.133 11.640 31.760
Overall 19.300 3.428 12.581 26.019 37.800 8.792 20.568 55.032
MARCO H 24.800 6.094 12.856 36.744 53.300 16.525 20.911 85.689
L 15.600 1.710 12.248 18.952 23.300 5.664 12.199 34.401
Overall 19.300 3.428 12.581 26.019 37.800 8.792 20.568 55.032
PAMR1 H 29.300 7.881 13.853 44.747 69.500 7.445 54.908 84.092
L 16.400 3.616 9.312 23.488 21.100 1.762 17.647 24.553
Overall 19.300 3.428 12.581 26.019 37.800 8.792 20.568 55.032
CRHBP H 55.600 13.080 29.964 81.236
L 27.500 7.523 12.754 42.246
Overall 37.800 8.792 20.568 55.032
DNASE1L3 H 55.600 6.310 43.232 67.968
L 23.300 5.103 13.298 33.302
Overall 37.800 8.792 20.568 55.032
FCN2 H 53.300 12.677 28.453 78.147
L 30.600 10.341 10.331 50.869
Overall 37.800 8.792 20.568 55.032
MT1X H 58.800 12.301 34.690 82.910
L 23.300 5.997 11.546 35.054
Overall 37.800 8.792 20.568 55.032
VIPR1 H 51.300 7.615 36.374 66.226
L 20.600 5.643 9.540 31.660
Overall 37.800 8.792 20.568 55.032
The gene expression and survival data of 157 HCC patients in a TCGA cohort were used for the analysis. Expression values of a gene were dichotomised into high
and low expression using the median as a cutoff
H high expression, L low expression
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shown in Table 4, we found that six genes—CXCL14,
GMNN, INTS8, MT1F, MT1G, and SPRX—were
expressed at low levels in HCC patients aged ≥ 65 years.
Expression of five genes was related to the gender of
HCC patients. Except for FCN2, which is lowly
expressed in male HCC patients, the other four genes,CLEC1B, CRHBP, MT1G, and TBCE, were all lowly
expressed in female HCC patients. In addition,
PAMR1 and MT1X were closely related to the vital
status; both showed low expression in 60.3 % (38/63)
of HCC patients with dead status, compared with high
expression in 57.4 % (54/94) of patients with alive sta-
tus (P = 0.022).
Fig. 3 Association of seven genes (ACSM3, CXCL14, CRHBP,
DNASE1L3, FCN2, MT1X, and VIPR1) with DFS or OS, analysed using
Kaplan-Meier survival plots. The survival data of 157 HCC patients
in a TCGA cohort were used for the analysis. Expression values of a
gene were dichotomised into high expression (blue line) and low
expression (green line) using the median as a cutoff
Fig. 4 Association of INTS8, LCAT, MARCO, and PAMR1 with DFS and
OS, analysed using Kaplan-Meier survival plots. The survival data of
157 HCC patients in a TCGA cohort were used for the analysis.
Expression values of a gene were dichotomised into high expression
(blue line) and low expression (green line) using the median as a cutoff
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The potential roles of the 20 genes in HCC were
predicted on the basis of Coremine Medical mining. As
shown in Fig. 5, the associations of the genes with diag-
nosis, prognosis, drug resistance, recurrence, metastasis,
and invasiveness of HCC was comprehensively analysed.
The results indicated that, with the exception of PAMR1,
the other 19 genes were all associated with at least one
factor contributing to cancer progression, and many of
the genes, for example GMNN, CXCL14, MT1G, MT1X,
SPRX, and VIPR1, were closely associated with almostall of the factors included in this analysis. Most of the
genes were extensively associated with several factors.
For example, 15 genes (including INTS8, LCAT,
MARCO, and DANSE1L3) were associated with diagno-
sis, 14 genes (including INTS8, MARCO, CRHBP, and
VIPR1) were associated with metastasis, and 13 genes
(including LCAT, MARCO, FCN2, and CXCL14) were
associated with prognosis.
Based on the gene expression in two independent
GEO microarrays corresponding to HCC metastasis, the
association of the genes CLEC4M, CRHBP, MARCO,
MT1X, SRPX, UBAP2L, and VIPR1 with metastasis was
Table 3 Multivariate analysis of prognosis of 157 HCC patients in a TCGA cohort using Cox proportional hazard model
Factors B SE Wald df Sig. Exp(B) 95.0 % CI
Lower Upper
CRHBP -.267 1.272 .044 1 .834 .766 .063 9.268
DNASE1L3 -.969 .476 4.140 1 .042 .379 .149 .965
FCN2 .517 .896 .333 1 .564 1.676 .290 9.704
INTS8 .204 .090 5.175 1 .023 1.227 1.029 1.463
LCAT .030 .194 .024 1 .877 1.031 .704 1.509
MARCO -.070 .859 .007 1 .935 .932 .173 5.020
MT1X .788 1.051 .561 1 .454 2.198 .280 17.256
PAMR1 -.158 .236 .448 1 .503 .854 .538 1.355
VIPR1 .194 .287 .459 1 .498 1.215 .692 2.131
Stage (I/II–III) .901 .463 3.784 1 .050 2.462 .993 6.101
PT (1–2/3–4) -.223 .426 .273 1 .601 .800 .347 1.844
Residual (R0/R1–2) -.175 .586 .089 1 .765 .839 .266 2.649
Tumour status (free/with) 1.300 .404 10.359 1 .001 3.669 1.662 8.097
Vital status (dead/alive) −13.599 55.193 .061 1 .805 .000 .000 1.2e + 41
Age .000 .014 .001 1 .981 1.000 .974 1.028
Gender -.276 .312 .781 1 .377 .759 .412 1.399
PT AJCC Tumour Pathologic PT
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were unavailable. The expression of CRHBP, LCAT, and
SPRX was significantly dysregulated in nine HCCs with
venous metastasis compared with 11 HCC without
(Fig. 6a). Genes VIPR1, LCAT, BAP2L, CLEC4M, CRHBP,
and SRPX were significantly dysregulated in 32 HCCs
with portal vein tumour thrombus metastasis and 33
HCCs with intrahepatic spread metastasis compared
with 22 HCCs with no metastasis (Fig. 6b&c). In particu-
lar, LCAT was highly expressed in HCC patients with
venous metastasis and patients with portal vein tumour
thrombus metastasis, and SRPX was lowly expressed in
HCC patients with venous metastasis and patients with
intrahepatic spread metastasis (Fig. 6).
Correlation of DNA methylation with mRNA expression of
the target genes
DNA methylation and mRNA expression data from 379
HCC patients in a TCGA cohort were retrieved and the
correlations between them were analysed using bivariate
correlations. Among the 20 genes that are poorly studied
in HCC (Table 1), DNA methylation data of CLEC1B
and SRPX were not available. DNA methylation was
negatively correlated with the mRNA expression for
eight genes, ACSM3, INTS8, LCAT, MT1X, CRHBP,
MARCO, PAMR1, and VIPR1. In particular, high methy-
lation of the first four genes was significantly correlated
with lower mRNA expression (Fig. 7), indicating that the
expression of these genes in HCC might be regulated by
DNA methylation.Discussion
Cancer is frequently considered to be a disease of the
cell cycle because alterations in different families of cell
cycle regulators cooperate in tumour development.
Molecular analysis of human tumours has shown that
cell cycle regulators are frequently mutated in human
neoplasms, underscoring the importance of maintain-
ing cell cycle commitment in the prevention of human
cancer [26]. Abnormal expression of cell cycle control-
lers, particularly G1/S-phase transition, is often impli-
cated in the pathogenesis of most human cancers,
including HCC. For example, vaccinia-related kinase 1
promotes HCC by controlling the levels of cell cycle
regulators associated with G1/S transition [27]. In this
study, 80 genes that were significantly dysregulated in
HCC were identified based on four independent microar-
rays covering a total of 386 cases of hepatocellular carcin-
oma and 327 cases of normal liver tissues (Fig. 1), and
biological process annotation of these genes revealed that
17 of these genes were implicated in cell cycle functions
(Additional file 1: Table S1). These results suggested that
these genes might contribute to cancer progression and
development in HCC at least in part through regulation of
the cell cycle.
Twenty-seven genes were further identified to be con-
sistently dysregulated in all four microarrays by at least
2-fold (Table 1). The expression of eight of these genes
(TBCE, INTS8, VIPR1, CLEC4M, MARCO, DNASE1L3,
CRHBP, and FCN2) was confirmed in 11 tissues of HCC
patients compared with matched paracancerous tissues
Table 4 Associations of genes expression with AJCC tumour pathologic PT, tumour stage, age and gender in 157 patients with hepatocellular carcinoma
Factors No. of patients ACSM3 FCN2 INTS8 LCAT MT1G UBAP2L
High Low High Low High Low High Low High Low High Low
PT 157 P = 0.037 P = 0.026 P = 0.046 P = 0.000 P = 0.016 P = 0.004
T1 62 (39.5 %) 39 (62.9 %) 23 (37.1 %) 39 (62.9 %) 23 (37.1 %) 23 (37.1 %) 39 (62.9 %) 45 (72.6 %) 17 (27.4 %) 39 (62.9 %) 23 (37.1 %) 22 (35.5 %) 40 (64.5 %)
T2 40 (25.5 %) 20 (50.0 %) 20 (50.0 %) 13 (32.5 %) 27 (67.5 %) 24 (60.0 %) 16 (40.0 %) 12 (30.0 %) 28 (70.0 %) 13 (32.5 %) 27 (67.5 %) 29 (72.5 %) 11 (27.5 %)
T3 46 (29.3 %) 16 (34.8 %) 30 (65.2 %) 22 (47.8 %) 24 52.2 %) 28 (60.9 %) 18 (39.1 %) 18 (39.1 %) 28 (60.9 %) 21 (45.7 %) 25 54.3 %) 23 (50.0 %) 23 (50.0 %)
T4 9 (5.7 %) 4 (44.4 %) 5 (55.6 %) 4 (44.4 %) 5 (55.6 %) 4 (44.4 %) 5 (55.6 %) 4 (44.4 %) 5 (55.6 %) 6 (66.7 %) 3 (33.3 %) 5 (55.6 %) 4 (44.4 %)
Stage 143 P = 0.016 P = 0.032 P = 0.026 P = 0.000 P = 0.037 P = 0.009
I 59 (41.3 %) 36 (61.0 %) 23 (39.0 %) 36 (61.0 %) 23 (39.0 %) 23 (39.0 %) 36 (61.0 %) 42 (71.2 %) 17 (28.8 %) 37 (62.7 %) 22 (37.3 %) 22 (37.3 %) 37 (62.7 %)
II 36 (25.2 %) 19 (52.8 %) 17 (47.2 %) 12 (33.3 %) 24 (66.7 %) 22 (61.1 %) 14 (38.9 %) 12 (33.3 %) 24 (66.7 %) 13 (36.1 %) 23 (63.9 %) 25 (69.4 %) 11 (30.6 %)
III 48 (33.6 %) 16 (33.3 %) 32 66.7 %) 25 (52.1 %) 23 (47.9 %) 30 (62.5 %) 18 (37.5 %) 18 (37.5 %) 30 (62.5 %) 23 (47.9 %) 25 (52.1 %) 25 (52.1 %) 23 (47.9 %)
CXCL14 GMNN INTS8 MT1F MT1G SPRX
High Low High Low High Low High Low High Low High Low
Agea 157 P = 0.031 P = 0.031 P = 0.005 P = 0.013 P = 0.031 P = 0.031
< 65 80 (51.0 %) 47 (58.8 %) 33 (41.3 %) 47 (58.8 %) 33 (41.3 %) 49 (61.2 %) 31 (38.8 %) 47 (58.8 %) 32 (40.0 %) 47 (58.8 %) 33 (41.3 %) 47 (58.8 %) 33 (41.3 %)
≥ 65 77 (49.0 %) 32 (41.6 %) 45 (58.4 %) 32 (41.6 %) 45 (58.4 %) 30 (39.0 %) 47 (61.0 %) 32 (41.6 %) 46 (59.7 %) 32 (41.6 %) 45 (58.4 %) 32 (41.6 %) 45 (58.4 %)
CLEC1B CRHBP FCN2 MT1G TBCE
High Low High Low High Low High Low High Low
Gender 157 P = 0.003 P = 0.019 P = 0.043 P = 0.003 P = 0.019
Female 62 (39.5 %) 22 (35.5 %) 40 (64.5 %) 24 (38.7 %) 38 (61.3 %) 25 (61.0 %) 37 (39.0 %) 22 (35.5 %) 40 (64.5 %) 24 (38.7 %) 38 (61.3 %)
Male 95 (60.5 %) 57 (60.0 %) 38 (40.0 %) 55 (57.9 %) 40 (42.1 %) 54 (56.8 %) 41 (43.2 %) 57 (60.0 %) 38 (40.0 %) 55 (57.9 %) 40 (42.1 %)
aAge was dichotomised into < 65 and ≥ 65 using the median as a cutoff. PT, AJCC Tumour Pathologic PT. Expression values of a gene were dichotomised into high and low expression using the median as a cutoff. P













Fig. 5 Association of the genes with HCC characteristics was
determined by text mining using Coremine Medical and probabilistic
scoring (P < 0.05). HCC: hepatocellular carcinoma, DR: drug resistance
Fig. 6 mRNA expression of the genes in HCC patients with and
without metastasis according to microarray data retrieved from the
GEO online database. a Microarray data GDS3091 [18] cover nine HCCs
with venous metastasis and 11 without as controls. b, c Microarray
data GDS274 [19] cover 32 HCCs with portal vein tumour thrombus
metastasis, 33 with intrahepatic spread metastasis, and 22 HCCs with
no metastasis as controls. *, P < 0.05; **, P < 0.01
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PTTG1, CAP2, TOP2A, GPC3, EGR1, and NAT2) have
been well studied in HCC (Table 1). For example,
GPC3 plays critical roles in cell proliferation and inva-
sion through the induction of apoptosis [28] and is a
biomarker for diagnosis [29] and recurrence [30]. Pro-
tein/gene-protein/gene interaction analyses indicated
that these 27 proteins/genes strongly interacted with
each other, and 10 of them interacted with at least half
of all the genes (Additional file 2: Figure S2). Moreover,
six of these genes were related to the cell cycle in HCC
(Additional file 1: Table S1). Together, these results
indicate that the genes identified in this study might
play crucial roles in HCC progression, probably function-
ing as a group.
Biomarkers not only have prognostic implications, but
are also helpful for measurement of treatment responses
and surveillance for tumour recurrence and for guiding
clinical decisions [31]. Thus, prognostic biomarkers for
HCC patients are necessary and crucial, and there is an
ongoing search for predictive biomarkers. In this study,
a group of genes associated with DFS and OS (Table 2)
were identified in 157 HCC patients. Among these
genes, low expression of ACSM3 and CXCL14 was
associated with poor DFS, low expression of CRHBP,
DNASE1L3, FCN2, MT1X, and VIPR1 was associated
with poor OS (Fig. 3, Table 2), high expression of
INTS8 was associated with poor DFS and OS, and low
expression of LCAT, MARCO, and PAMR1 was associated
with poor DFS and OS (Fig. 4, Table 2). Furthermore,
DNASE1L3 and INTS8 were identified as independent risk
prognostic factors for OS (Table 3). There are few reports
of the association of these genes with prognosis in
HCC or in other cancers. Previous studies indicate thatdownregulation of CXCL14 is associated with prognosis
in gastric cancer patients [32], MT1X may aid in the
prognostic discrimination of oral squamous cell carcin-
oma cases [33], and MARCO expression is associated
with breast cancer survival and risk of recurrence [34].
Twenty genes that have been less studied in HCC
(Table 1) were further evaluated to predict their poten-
tial roles in HCC progression. Coremine medical mining
suggested that most of those genes were associated with
Fig. 7 DNA methylation of four genes was significantly and negatively correlated with their mRNA expression. Data for gene expression and DNA
methylation in 379 HCCs were retrieved from a TCGA cohort. The correlation between DNA methylation and gene expression was analysed using
bivariate correlations
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tasis, and invasiveness. In particular, 13, 14, and 15 genes
were potentially associated with prognosis, metastasis,
and diagnosis in HCC, respectively (Fig. 5). The associ-
ation of these genes with prognosis appears to have
clinical importance, as 11 genes were shown to be asso-
ciated with DFS or/and OS (Table 2, Fig. 3 & 4). The
role of these genes in metastasis was further confirmed
by gene expression analysis, which showed that five
genes were significantly dysregulated in HCC with ven-
ous metastasis, portal vein tumour thrombus metastasis,
or intrahepatic spread metastasis, compared with the
appropriate controls. Specifically, LCAT was highly
expressed in HCC patients with venous metastasis and
patients with portal vein tumour thrombus metastasis,
and SRPX was lowly expressed in HCC patients with
venous metastasis and patients with intrahepatic spread
metastasis (Fig. 6), suggesting that these two genes
might be closely related to HCC metastasis. There are
few studies on LCAT and SRPX in cancer metastasis,
with only one reported that SRPX is upregulated in gastric
cancer cells after depletion of TWIST, which promoted
the epithelial-mesenchymal transition that occurs during
the initial steps of tumour metastasis [35].INTS8 encodes a subunit of the integrator complex
that is involved in the cleavage of small nuclear RNAs,
and its association with cancer is poorly understood.
Limited studies indicate that INTS8 contains mutations
in peripheral T cell lymphoma compared with non-
malignant samples from 12 patients [36], and a combin-
ation of INTS8 with SULF1, ATP6V1C1, and GPR172A
can be used to discriminate gastric carcinomas from adja-
cent noncancerous tissues [37]. In this study, we found
that, potentially regulated by demethylation (Fig. 7),
INTS8 was significantly and consistently upregulated at
least 2.115-fold in HCC according to four independent
microarrays (Fig. 1; Table 1) and that INTS8 mRNA was
upregulated 2.06-fold on average in 11 tissues of HCC
patients compared with corresponding paracancerous tis-
sues, with a similar expression profile at the protein level
(Fig. 2). Based on the clinical importance analysis of 157
HCC patients in a TCGA cohort, we found that high
expression of INTS8 was associated with poor DFS and
OS (Fig. 4, Table 2), and was an independent risk prognos-
tic factor for OS (Table 3). Moreover, high expression of
INTS8 was associated with metastatic tumours and late
stage (Table 4), and with younger HCC patients (<65 years
old) (Table 4). In addition, text mining indicated that
Yin et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:127 Page 13 of 14INTS8 was closely related with metastasis, invasiveness,
and diagnosis (Fig. 5). The above results strongly indicate
that this gene is indeed upregulated in HCC, where it
might play crucial roles in HCC cancer progression and
development, and is a potential biomarker for diagnosis
and, in particular, prognosis.
Conclusion
In summary, by means of data retrieved from six inde-
pendent microarrays, RT-qPCR and western blotting
detection in 11 pairs of tissues, clinical importance ana-
lyses in a cohort of 157 patients, and bioinformatics
analyses including biological process annotation, pro-
tein interaction and text mining, we have identified a
group of genes that are significantly dysregulated in
HCC and might be associated with cancer progression,
development, and, in particular, prognosis. These genes
could be potential therapeutic targets for HCC treat-
ment, and might be useful biomarkers for diagnosis and
prognosis.
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